p53 Mutations analysis in benign and malignant lesions: Using needle rinses from fine-needle aspirations

Diagnostic Cytopathology

Volumn 22, Issue 5, 2000, Pages 268-274

  Gudlaugsdottir, Sigfridur ^a   Sigurdardottir, Valgerdur ^a   Snorradottir, Margret ^a   Jonasson, Jon Gunnlaugur ^b   Ogmundsdottir, Helga ^a   Eyfjord, Jorunn Erla ^a  

^a ICELANDIC CANCER SOCIETY   (Iceland)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

Benign breast lesions; FNA; p53 gene

Indexed keywords

PHOSPHATE; SODIUM CHLORIDE;

ARTICLE; ASPIRATION BIOPSY; CONTROLLED STUDY; CYTOLOGY; GEL ELECTROPHORESIS; GENE MUTATION; HUMAN; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

BIOPSY, NEEDLE; BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, P53; HUMANS; MUTATION;

EID: 0034008671     PISSN: 87551039     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0339(200005)22:5<268::AID-DC2>3.0.CO;2-X     Document Type: Article

References (31)

1. Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 1985;55:2698-2708.
2. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146-151.
3. Dupont WD, Page DL, Parl FF, Vnencak-Jones CL, Plummer WD Jr., Rados MS, Schuyler PA. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med 1994;331:10-15.
4. Crawford LV, Pim DC, Lamb P. The cellular protein p53 in human tumours. Mol Biol Med 1984;2:261-272.
5. Koutselini H, Malliri A, Field JK, Spandidos DA. p53 expression in cytologic specimens from benign and malignant breast lesions. Anti-cancer Res 1991;11:1415-1419.
6. Stephenson TJ, Royds JA, Silcocks PB, Brammer HJ, Shorthouse AJ, Underwood JC. Diagnostic associations of p53 immunostaining in fine needle aspiration cytology of the breast. Cytopathology 1994;5:146-153.
7. Younes M, Lebovitz RM, Bommer KE, Cagle PT, Morton D, Khan S, Laucirca R. p53 accumulation in benign breast biopsy specimens. Hum Pathol 1995;26:155-158.
8. Fabian CJ, Zalles C, Kamel S, Zeiger S, Simon C, Kimler BF. Breast cytology and biomarkers obtained by random fine needle aspiration: use in risk assessment and early chemoprevention trials. J Cell Biochem [Suppl] 1997;28-29:101-110.
9. Rohan TE, Hartwick W, Miller AB, Kandel RA. Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. JNCI 1998;90:1262-1269.
10. Lisboa BW, Vogtlander S, Gilster T, Riethdorf L, Milde-Langosch K, Loning T. Molecular and immunohistochemical analysis of p53 mutations in scrapings and tissue from preinvasive and invasive breast cancer. Virchows Arch 1997 Dec;431(6):375-381.
11. Millikan R, Hulka B, Thor A, Zhang Y, Edgerton S, Zhang X, Pei H, He M, Wold L, Melton LJ. p53 mutations in benign breast tissue. J Clin Oncol 1995;13:2293-2300.
12. O'Connell P, Pekkel V, Fuqua S, Osborne CK, Allred DC. Molecular genetic studies of early breast cancer evolution. Breast Cancer Res Treat 1994;32:5-12.
13. Lakhani SR, Collins N, Stratton MR, Sloane JP. Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J Clin Pathol 1995;48:611-615.
14. Micale MA, Visscher DW, Gulino SE, Wolman SR. Chromosomal aneuploidy in proliferative breast disease. Hum Pathol 1994;25:29-35.
15. O'Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. JNCI 1998;90:697-703.
16. Kasami M, Vnencak-Jones CL, Manning S, Dupont WD, Page DL. Loss of heterozygosity and microsatellite instability in breast hyperplasia. No obligate correlation of these genetic alterations with subsequent malignancy. Am J Pathol 1997;150:1925-1932.
17. Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 1996; 274:2057-2059.
18. Borresen AL, Hovig E, Smith-Sorensen B, Malkin D, Lystad S, Andersen TI, Nesland JM, Isselbacher KJ, Friend SH. Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci USA 1991;88:8405-8409.
19. Thorlacius S, Borresen AL, Eyfjord JE. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res 1993;53:1637-1641.
20. Chou Q, Russell M, Birch DE, Raymond J, Bloch W. Prevention of pre-PCR mis-priming and primer dimerization improves low-copy-number amplifications. Nucleic Acids Res 1992;20:1717-1723.
21. Valgardsdottir R, Tryggvadottir L, Steinarsdottir M, Olafsdottir K, Jonasdottir S, Jonasson JG, Ogmundsdottir HM, Eyfjord JE. Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis. Acta Pathol Microbiol Immunol Scand 1997;105:121-130.
22. Fisher CJ, Gillett CE, Vojtesek B, Barnes DM, Millis RR. Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br J Cancer 1994;69:26-31.
23. Thorlacius S, Thorgilsson B, Bjornsson J, Tryggvadattir L, Borresen AL, Ogmundsdottir HM, Eyfjord JE. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis. Eur J Cancer 1995;31:1856-1861.
24. Kovach JS, Hartmann A, Blaszyk H, Cunningham J, Schaid D, Sommer SS. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA 1996;93:1093-1096.
25. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995;1:1029-1034.
26. Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Borresen AL. Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 1993;68:540-548.
27. Elledge RM, Fuqua SA, Clark GM, Pujol P, Allred DC, McGuire WL. Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat 1993;26:225-235.
28. Hartmann A, Blaszyk H, Kovach JS, Sommer SS. The molecular epidemiology of p53 gene mutations in human breast cancer. Trends Genet 1997;13:27-33.
29. Gretarsdottir S, Tryggvadottir L, Jonasson JG, Sigurdsson H, Olfasdottir K, Agnarsson BA, Ogmundsdottir HM, Eyfjord JE. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material. Br J Cancer 1996;74:555-561.
30. Borresen AL, Andersen TI, Eyfjord JE, Cornelis RS, Thorlacius S, Børg A, Johansson U, Theillet C, Scherneck S, Hartman S. et al. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer 1995;14:71-75.
31. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PA. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996;2:811-814.